Wetherby Asset Management Inc. Sells 15 Shares of C.R. Bard, Inc. (BCR)
Wetherby Asset Management Inc. decreased its position in C.R. Bard, Inc. (NYSE:BCR) by 0.5% during the second quarter, Holdings Channel reports. The firm owned 2,790 shares of the medical instruments supplier’s stock after selling 15 shares during the period. Wetherby Asset Management Inc.’s holdings in C.R. Bard were worth $882,000 as of its most recent filing with the SEC.
Several other large investors have also bought and sold shares of the company. Cribstone Capital Management LLC acquired a new stake in C.R. Bard during the first quarter worth $130,000. Whittier Trust Co. increased its stake in C.R. Bard by 7.7% in the first quarter. Whittier Trust Co. now owns 591 shares of the medical instruments supplier’s stock worth $147,000 after buying an additional 42 shares during the period. ClariVest Asset Management LLC acquired a new stake in C.R. Bard during the first quarter worth $148,000. SRS Capital Advisors Inc. increased its stake in C.R. Bard by 0.7% in the first quarter. SRS Capital Advisors Inc. now owns 598 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 4 shares during the period. Finally, Parallel Advisors LLC increased its stake in C.R. Bard by 283.8% in the first quarter. Parallel Advisors LLC now owns 499 shares of the medical instruments supplier’s stock worth $153,000 after buying an additional 369 shares during the period. 85.32% of the stock is owned by institutional investors and hedge funds.
C.R. Bard, Inc. (NYSE:BCR) opened at 319.13 on Friday. The company has a market capitalization of $23.19 billion, a price-to-earnings ratio of 41.90 and a beta of 0.59. C.R. Bard, Inc. has a 52-week low of $203.63 and a 52-week high of $323.27. The company’s 50-day moving average is $318.89 and its 200-day moving average is $282.81.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million for the quarter, compared to analysts’ expectations of $976.53 million. During the same period in the previous year, the business posted $2.54 EPS. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, analysts expect that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 4th. Investors of record on Monday, July 24th were paid a $0.26 dividend. This represents a $1.04 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend was Thursday, July 20th. C.R. Bard’s dividend payout ratio is currently 13.67%.
Several equities research analysts have commented on BCR shares. Cowen and Company upped their target price on shares of C.R. Bard from $240.00 to $317.00 and gave the company a “market perform” rating in a research note on Monday, April 24th. BidaskClub raised shares of C.R. Bard from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 8th. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $351.00 target price for the company in a research note on Tuesday, June 6th. Jefferies Group LLC upped their target price on shares of C.R. Bard from $237.00 to $317.00 and gave the company a “hold” rating in a research note on Monday, April 24th. Finally, Wells Fargo & Company downgraded shares of C.R. Bard from an “outperform” rating to a “market perform” rating in a research note on Tuesday, April 25th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $285.67.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.